Alle patienterne i det kliniske fase 3 studium oplevede bivirkninger (Adverse Drug Reactions – ADR' er), uanset om de modtog Naglazyme eller placebo.
All patients in the Phase 3 clinical study experienced Adverse Drug Reactions (ADRs), regardless of whether they were receiving Naglazyme or placebo.